Literature DB >> 1523913

Serum ceruloplasmin in acute myocardial infarction.

T K Singh1.   

Abstract

Serum ceruloplasmin levels were estimated in 81 patients within one week after an attack of acute myocardial infarction. A total of 126 healthy subjects were taken as controls and investigated for this copper containing protein. Results showed that there is an elevation in the levels of serum ceruloplasmin in patients as compared to the controls. Ceruloplasmin levels showed a return to almost normal values in 54 follow-up cases of acute myocardial infarction during the fourth week after infarction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1523913

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  5 in total

1.  Clinical and genetic association of serum ceruloplasmin with cardiovascular risk.

Authors:  W H Wilson Tang; Yuping Wu; Jaana Hartiala; Yiying Fan; Alexandre F R Stewart; Robert Roberts; Ruth McPherson; Paul L Fox; Hooman Allayee; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-10       Impact factor: 8.311

2.  Copper futures: ceruloplasmin and heart failure.

Authors:  Dian J Cao; Joseph A Hill
Journal:  Circ Res       Date:  2014-05-23       Impact factor: 17.367

3.  Direct evidence of caeruloplasmin antioxidant properties.

Authors:  R L Atanasiu; D Stea; M A Mateescu; C Vergely; F Dalloz; F Briot; V Maupoil; R Nadeau; L Rochette
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

Review 4.  Nitrite and nitrate chemical biology and signalling.

Authors:  Anthony W DeMartino; Daniel B Kim-Shapiro; Rakesh P Patel; Mark T Gladwin
Journal:  Br J Pharmacol       Date:  2018-10-03       Impact factor: 8.739

5.  Ceruloplasmin, NT-proBNP, and Clinical Data as Risk Factors of Death or Heart Transplantation in a 1-Year Follow-Up of Heart Failure Patients.

Authors:  Ewa Romuk; Wojciech Jacheć; Ewa Zbrojkiewicz; Alina Mroczek; Jacek Niedziela; Mariusz Gąsior; Piotr Rozentryt; Celina Wojciechowska
Journal:  J Clin Med       Date:  2020-01-03       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.